ClinicalTrials.gg
RecruitingNCT06695845Updated Nov 4, 2026

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

A Phase 2 interventional study of Zanidatamab in Breast Cancer, Gastric Cancer and Esophageal Cancer, sponsored by Jazz Pharmaceuticals. Recruiting at 42 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 4, 2026First site in Georgia14 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

02

Conditions studied

  • Breast Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Gastroesophageal Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Non-small Cell Lung Cancer
  • Ovarian Cancer
  • Urothelial Carcinoma
  • Salivary Gland Cancer
  • Pancreatic Cancer
  • HER-2 Protein Overexpression

Keywords

  • JZP598
  • ZW25
  • HER2 IHC 3+ Overexpression Solid Tumors
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 200 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is at least 18 years of age inclusive at the time of signing the
  2. Participants with locally advanced, unresectable, or solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or cholangiocarcinoma) who have progressed following at least 1 prior systemic treatment for metastatic or advanced disease and have no available treatment options that have confirmed benefit. Prior treatment with -targeted therapy is not permitted (Cohort 1 only). For participants with breast cancer (Cohort 2) or GEA (Cohort 3), prior HER2-targeted therapy is permitted and prior therapy with trastuzumab deruxtecan (T-DXd) is required.
  3. HER2 overexpression (IHC 3+) must be determined by a sponsor designated central laboratory.
  4. All participants must have adequate tumor sample for submission to allow central HER2 testing.
  5. Presence of at least 1 as assessed by Independent Central Review (ICR) based on Version 1.1 (RECIST 1.1)
  6. Has (ECOG) performance status of 0 or 1.
  7. Has a of at least 3 months, in the opinion of the investigator.
  8. Participants with history of treated and stable are eligible, provided the following criteria are met:

    1. Participants also have measurable metastatic disease with HER2 overexpression (IHC 3+) outside the CNS.
    2. Participants with treated CNS metastases that are no longer symptomatic may be included in the study if they recovered to \< Grade 1 ( Version 5.0 or higher) or baseline from the acute toxic effect associated with the treatment > 7 days prior to Cycle 1 Day 1.
    3. Prior stereotactic radiosurgery or stereotactic radiotherapy should be completed at least 7 days (≥ 7 days) before the first dose of study intervention.
  9. Adequate organ functions.
  10. Females of must have a negative pregnancy test result.
  11. Females of childbearing potential and males with a partner of childbearing potential must be willing to use 2 methods of .

Exclusion criteria

Exclusion Criteria:

  1. Has known or suspected and/or untreated .
  2. Has uncontrolled or significant cardiovascular disease
  3. Has ongoing toxicity related to prior cancer therapy
  4. Has uncontrolled infection or requiring IV antibiotics, antivirals, or antifungals.
  5. Has known (HIV) infection.
  6. Has active or C infection.
  7. Has an active SARS-CoV-2 infection.
  8. Has a history of life-threatening to monoclonal antibody (mAbs) or to recombinant proteins or in the drug formulation of zanidatamab.
  9. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the site.
  10. Has any issue or condition that, in the opinion of the investigator, would contraindicate the participant's participation in the study or confound the results of the study.
  11. Prior treatment with -targeted therapy (Cohort 1 only).
  12. Has a history of trauma or major surgery
  13. Was treated with systemic antineoplastic therapy, including hormonal therapies for breast cancer, or any investigational therapy within 4 weeks or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  14. Received zanidatamab at any time prior to the current study.
  15. Colorectal Cancer (CRC) participants with known KRAS/NRAS and BRAF mutations.
  16. Non-Small Cell Lung Cancer (NSCLC) participants with known ALK, EGFR mutations and ROS1 fusion.
  17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.
  18. Prior or concurrent invasive other than the disease under study, whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the investigational regimen.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Zanidatamab treatment arm

    Eligible participants receiving zanidatamab treatment

    Drug: Zanidatamab

Interventions

  • Administered by intravenous (IV) infusion

    Also known as: ZW25, JZP598, ZIIHERA®

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (cORR) per RECIST Version 1.1, as assessed by ICR

    The Independent Central Review (ICR) assessed cORR is defined as the proportion of participants who had a best overall response of Complete Response (CR), or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    Time frame: Up to 2.5 years

Secondary outcomes

  1. Duration of Response (DOR) Per RECIST Version 1.1, as assessed by ICR

    ICR assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented progressive disease (PD) per RECIST v1.1 or death from any cause.

    Time frame: Up to 2.5 years

  2. cORR by RECIST Version 1.1, as assessed by Investigator

    Investigator assessed cORR is defined as the proportion of participants who had a best overall response of Complete Response (CR), or Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

    Time frame: Up to 2.5 years

  3. Duration of Response (DOR) Per RECIST Version 1.1, as assessed by Investigator

    Investigator assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented progressive disease (PD) per RECIST v1.1 or death from any cause.

    Time frame: Up to 2.5 years

  4. Time to Response (TTR), as assessed by ICR

    ICR assessed TTR is defined as the time from the first dosing date to the first objective response (CR or PR) per RECIST v1.1.

    Time frame: Up to 2.5 years

  5. Time to Response (TTR), as assessed by Investigator

    Investigator assessed TTR is defined as the time from the first dosing date to the first objective response (CR or PR) per RECIST v1.1.

    Time frame: Up to 2.5 years

  6. Disease control rate (DCR), as assessed by ICR

    ICR assessed DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed CR, or PR, or stable disease using the RECIST version 1.1 criteria

    Time frame: Up to 2.5 years

  7. Disease control rate (DCR), as assessed by Investigator

    Investigator assessed DCR is defined as the proportion of participants whose best overall response (BOR) is confirmed CR, or PR, or stable disease using the RECIST version 1.1 criteria

    Time frame: Up to 2.5 years

  8. Progression Free Survival (PFS), as assessed by ICR

    PFS is defined as the time in months from the first dosing date to the date of first documented disease progression (as assessed by ICR according to RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: Up to 2.5 years

  9. Progression Free Survival (PFS), as assessed by Investigator

    PFS is defined as the time in months from the first dosing date to the date of first documented disease progression (as assessed by Investigator according to RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: Up to 2.5 years

  10. Overall Survival (OS)

    OS is defined as the time in months from the first dosing date to the date of death due to any cause.

    Time frame: Up to 3.5 years

  11. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) As Graded by NCI CTCAE Version 5.0

    Time frame: Up to 2.5 years

  12. Number of Participants With Dose Reductions

    Time frame: Up to 2.5 years

  13. Number of Participants Discontinuing Study Treatment Due to TEAEs

    Time frame: Up to 2.5 years

  14. Serum Concentrations of Zanidatamab

    Time frame: Up to 2.5 years

  15. Number of Participants Positive for Anti-drug Antibodies to Zanidatamab

    Time frame: Up to 2.5 years

  16. Number of participants reporting Symptomatic Adverse Events based on Patient-reported Outcome-Common Terminology Criteria for AEs (PRO-CTCAE)

    Time frame: Up to 2.5 years

  17. Number of participants reporting Symptomatic Adverse Events based on European Organisation for Research and Treatment of Cancer (EORTC) Item Library

    Time frame: Up to 2.5 years

  18. Percentage of all treated participants reporting overall side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5)

    Time frame: Up to 2.5 years

  19. Percentage of time when participants on treatment reported a high side-effect bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5)

    Time frame: Up to 2.5 years

07

Study locations

30 of 42 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

Data sharing details ↗ · www.jazzpharma.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 23 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2024
First posted
Nov 19, 2024
StartActual
Jan 14, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites added — first site in Georgia
Show 14 added (7 Spain, 5 Georgia, 2 United States)
  • University of Kansas Cancer Center · Westwood, United States
  • Northwell Health Cancer Institute · Lake Success, United States
  • JSC Vian- Krystyna Kiel Oncology Center · Kutaisi, Georgia
  • LTD Todua Clinic · Tbilisi, Georgia
  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic LLC · Tbilisi, Georgia
  • Cancer Research Centre · Tbilisi, Georgia
  • LTD Caucasus Medical Centre · Tbilisi, Georgia
  • Hospital Universitario Insular Gran Canarias · Las Palmas, Spain
  • Complejo Hospitalario de Navarra · Pamplona, Spain
  • Hospital Universitario Vall d'Hebron · Barcelona, Spain
  • Hospital Clinic de Barcelona · Barcelona, Spain
  • Hospital Universitario Ramon y Cajal · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • INCLIVA, Hospital Clinico Universitario de Valencia · Valencia, Spain
Nov 4, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionOverall Survival (OS): how it is measured was reworded
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    14 sites added — first site in Georgia
    Show 14 added (7 Spain, 5 Georgia, 2 United States)
    • University of Kansas Cancer Center · Westwood, United States
    • Northwell Health Cancer Institute · Lake Success, United States
    • JSC Vian- Krystyna Kiel Oncology Center · Kutaisi, Georgia
    • LTD Todua Clinic · Tbilisi, Georgia
    • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic LLC · Tbilisi, Georgia
    • Cancer Research Centre · Tbilisi, Georgia
    • LTD Caucasus Medical Centre · Tbilisi, Georgia
    • Hospital Universitario Insular Gran Canarias · Las Palmas, Spain
    • Complejo Hospitalario de Navarra · Pamplona, Spain
    • Hospital Universitario Vall d'Hebron · Barcelona, Spain
    • Hospital Clinic de Barcelona · Barcelona, Spain
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • INCLIVA, Hospital Clinico Universitario de Valencia · Valencia, Spain
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionOverall Survival (OS): how it is measured was reworded
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06695845
Collaborators
Jazz Pharmaceuticals Ireland Limited
Responsible party
Sponsor
First posted
Nov 19, 2024
Start date
Jan 14, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Clinical Trial Disclosure & Transparency
Contact
ClinicalTrialDisclosure@JazzPharma.com
215-832-3750

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanidatamab

Start the discussion